pharma · Hypophosphatasia · Paroxysmal Nocturnal Hemoglobinuria
Alexion Pharma Germany is a pharma organization headquartered in EU. Primary therapeutic focus areas include Hypophosphatasia, Paroxysmal Nocturnal Hemoglobinuria, Lupus Nephritis (LN) Immunoglobulin A Nephropathy (IgAN)
Phase 2 · small molecule · Acromegaly
ALXN2420 is a growth hormone receptor antagonist in Phase 2 development by Alexion Europe SAS for the treatment of acromegaly. The program is evaluating ALXN2420 administered subcutaneously in combination with somatostatin analogs (octreotide acetate and lanreotide acetate) versus placebo in a randomized, double-blinde
Internal code ALXN2420-Acro-201
ALXN2420 is a growth hormone receptor antagonist in Phase 2 development by Alexion Europe SAS for the treatment of acromegaly. The program is evaluating ALXN2420 administered subcutaneously in combination with somatostatin analogs (octreotide acetate and lanreotide acetate) versus placebo in a randomized, double-blinded, dose range-finding multicenter study. Acromegaly is a rare endocrine disorder characterized by excessive growth hormone secretion, typically managed with somatostatin analogs as first-line therapy. ALXN2420 represents a potential combination strategy to enhance efficacy in patients with inadequate response to somatostatin analogs alone. The trial design incorporates both efficacy and safety assessments alongside pharmacokinetic evaluation. Octreotide acetate and lanreotide acetate are established, approved somatostatin analogs used as comparators and combination partners in this study. The program remains in active development with no disclosed regulatory milestones or approval timelines at this time. This combination approach addresses the clinical need for improved disease control in acromegaly patients who remain inadequately controlled on somatostatin analog monotherapy.
Acromegaly is a rare but serious endocrine disorder with significant morbidity including cardiovascular complications, metabolic dysfunction, and reduced quality of life. Current standard-of-care somatostatin analogs (octreotide and lanreotide) provide disease control in many patients, but a substantial proportion experience inadequate biochemical or clinical response, creating an unmet medical need for combination or alternative therapeutic approaches. ALXN2420's mechanism as a growth hormone receptor antagonist offers a mechanistically distinct approach that could complement somatostatin analog action through dual pathway inhibition. The competitive landscape includes multiple Phase 3 programs (Paltusotine from Crinetics, CAM2029 from Camurus, and Debio 4126 from Debiopharm) as well as Phase 2 programs (GHR-LRx from Ionis), indicating significant industry investment in acromegaly therapeutics. The market relevance is substantial given the chronic nature of acromegaly and the high treatment burden; combination therapies that improve efficacy could capture significant market share among the estimated 3,000–4,000 acromegaly patients in the United States alone. Alexion's strategy of combining a novel GHR antagonist with established somatostatin analogs may offer a pragmatic pathway to clinical benefit and regulatory approval, particularly if Phase 2 data demonstrate superior efficacy to either agent alone.
Drug Class: Growth hormone receptor antagonist (ALXN2420) combined with somatostatin analogs (octreotide acetate, lanreotide acetate).
Modality: Small molecule.
Route of Administration: Subcutaneous injection.
Mechanism of Action: ALXN2420 acts as a growth hormone receptor antagonist; octreotide acetate and lanreotide acetate are somatostatin receptor agonists that suppress growth hormone and insulin-like growth factor-1 (IGF-1) secretion.
Target: Growth hormone receptor (ALXN2420); somatostatin receptors (octreotide and lanreotide).
Related Therapies: Established somatostatin analogs (octreotide, lanreotide) are approved and widely used; pegvisomant is an approved GHR antagonist monotherapy; dopamine agonists (cabergoline, bromocriptine) are alternative agents.
Regulatory Status of Comparators: Octreotide acetate is approved in the United States under multiple ANDA and NDA applications (sponsors include Novartis, Teva, Mylan, and others); lanreotide (Ipsen's Lanreotide Autogel 120 mg) is approved.
Also known as: Growth hormone excess, pituitary giant, somatotroph adenoma
Prevalence: Point prevalence: 1-9 / 100 000 (Worldwide) — source: Orphanet, validated.
Acromegaly is an acquired disorder related to excessive production of growth hormone (GH) and characterized by progressive somatic disfigurement (mainly involving the face and extremities) and systemic manifestations.
ClinicalTrials.gov lists 9 registered studies for Growth Hormone (AACT aggregate).
Phase breakdown: NA (6), PHASE3 (2), PHASE2/PHASE3 (1)
Common investigational therapies:
Disease data sourced from MONDO Disease Ontology (MONDO:0019933), Orphanet — acromegaly, NCT00562796, NCT00966134, NCT01158612, NCT01540773, NCT04079010, AACT (ClinicalTrials.gov aggregate), ClinicalTrials.gov, Open Targets Platform (CC BY 4.0).
ALXN2420-Acro-201 ongoing
Phase 2 randomized, double-blinded, placebo-controlled, dose range-finding multicenter study evaluating ALXN2420 combined with somatostatin analogs in acromegaly.
The acromegaly therapeutic landscape includes multiple competitors at varying development stages. Approved therapies include octreotide and lanreotide (somatostatin analogs) and pegvisomant (GHR antagonist monotherapy). In Phase 3 development are Paltusotine (Crinetics Pharmaceuticals), a selective somatostatin receptor subtype-2 agonist; CAM2029 (Camurus), an octreotide subcutaneous depot formulation; and Debio 4126 (Debiopharm), a ready-to-use lanreotide suspension. In Phase 2 alongside ALXN2420 is GHR-LRx (Ionis Pharmaceuticals), another growth hormone receptor antagonist. ALXN2420's differentiation lies in its combination strategy with established somatostatin analogs rather than monotherapy, potentially offering synergistic efficacy for patients with inadequate response to single agents. Paltusotine and CAM2029 represent alternative monotherapy approaches in late-stage development. The competitive positioning suggests that multiple pathways to improved acromegaly control are being pursued, with combination therapy (ALXN2420) and novel formulations (CAM2029) competing alongside selective receptor agonists (Paltusotine) and other GHR antagonists (GHR-LRx).
| Therapy | Company | Mechanism | Status |
|---|---|---|---|
| Lanreotide Autogel 120 mg | Ipsen | small_molecule | approved |
| LANREOTIDE, LANREOTIDE, Debio 4126, Debio 4126, Ready-to-use suspension resembling 30, 60, or 90 mg Debio 4126 doses, Debio 4126, OCTREOTIDE, OCTREOTIDE, LANREOTIDE, OCTREOTIDE | Alphapharm Pty Ltd | small_molecule | phase_3 |
| Placebo to match Paltusotine tablets 20 mg, Paltusotine tablets | Lacuna Pharma Pty Ltd | small_molecule | phase_3 |
| CAM2029 (octreotide subcutaneous depot), CAM2029 (octreotide subcutaneous depot) | Camurus Pty Ltd | small_molecule | phase_3 |
| Paltusotine | Crinetics Pharmaceuticals Europe GmbH | small_molecule | phase_3 |
| Paltusotine tablets, Paltusotine tablets | Lacuna Pharma Pty Ltd | small_molecule | phase_2 |
| GHR-LRX | IONIS PHARMACEUTICALS INC | small_molecule | phase_2 |
| IONIS GHR-LRx | IONIS PHARMACEUTICALS INC | small_molecule | phase_2 |
| Preoperative lanreotide treatment | The First People's Hospital of Lianyungang | small_molecule | phase_2 |
| PEGVISOMANT | — | Growth hormone receptor antagonist | Approved |
| PASIREOTIDE PAMOATE | — | Somatostatin receptor 2 agonist | Approved |
| OCTREOTIDE ACETATE | — | Somatostatin receptor agonist | Approved |
| LANREOTIDE ACETATE | — | Somatostatin receptor 2 agonist | Approved |
| BROMOCRIPTINE MESYLATE | — | D2-like dopamine receptor agonist | Approved |
| PASIREOTIDE | — | Somatostatin receptor 5 agonist | Phase 3 |
| OCTREOTIDE | — | Somatostatin receptor agonist | Phase 3 |
| LANREOTIDE | — | Somatostatin receptor 5 agonist | Phase 3 |
| VELDOREOTIDE | — | Somatostatin receptor 5 agonist | Phase 2 |
| CLOMIPHENE CITRATE | — | Estrogen receptor alpha modulator | Phase 2 |
| CLOMIPHENE | — | Estrogen receptor alpha modulator | Phase 2 |
Additional associated therapies sourced from Open Targets Platform (CC0), linked to NovaPharmaNews drug profiles where matched.
United States: ALXN2420 regulatory status not yet disclosed. Octreotide acetate is approved under multiple ANDA and NDA applications (application numbers include ANDA075957, ANDA075959, ANDA076313, ANDA076330, ANDA077329, ANDA077330, ANDA077331, ANDA077372, ANDA077373, ANDA077450, ANDA077457, ANDA079198, ANDA090834, ANDA090985, ANDA090986, ANDA091041, ANDA203765, ANDA204669, ANDA210317, ANDA216589, ANDA216807, ANDA216839, ANDA217860, NDA019667, NDA021008, NDA208232, NDA213224) with multiple sponsors including Novartis, Teva Pharmaceuticals USA, Mylan, and others.
European Union: Regulatory status for ALXN2420 not yet disclosed. Lanreotide Autogel (Ipsen) is approved in Europe.
Japan (PMDA): Regulatory status not yet disclosed.
China (NMPA): Regulatory status not yet disclosed.
No filing, breakthrough designation, or approval timelines have been disclosed for ALXN2420.
ALXN2420 is being investigated for the treatment of acromegaly, a rare endocrine disorder characterized by excessive growth hormone secretion. In the current Phase 2 trial, it is being evaluated in combination with somatostatin analogs (octreotide or lanreotide) in patients with acromegaly.
No, ALXN2420 is not yet approved. It is currently in Phase 2 clinical development. No regulatory approval or filing status has been disclosed.
ALXN2420 is a growth hormone receptor antagonist that blocks the action of growth hormone at the receptor level. In the Phase 2 trial, it is combined with somatostatin analogs, which suppress growth hormone secretion, providing a dual mechanism of action.
ALXN2420 is being developed by Alexion Europe SAS, a subsidiary of Alexion Pharmaceuticals.
The indication under investigation is acromegaly, a rare disorder caused by excessive growth hormone production, typically from a pituitary adenoma.
ALXN2420 is administered as a subcutaneous injection in the Phase 2 trial.
ALXN2420 is in Phase 2 clinical development. The current trial is a randomized, double-blinded, placebo-controlled, dose range-finding study.
The trial compares ALXN2420 combined with somatostatin analogs (octreotide acetate or lanreotide acetate) versus placebo combined with somatostatin analogs.
The trial is a Phase 2, randomized, double-blinded, placebo-controlled, dose range-finding, multicenter study evaluating the efficacy, safety, and pharmacokinetics of ALXN2420 administered subcutaneously in combination with somatostatin analogs in adult participants with acromegaly.
The specific primary endpoints have not been disclosed in the available information. The trial is designed to evaluate efficacy, safety, and pharmacokinetics.
A substantial proportion of acromegaly patients have inadequate biochemical or clinical response to somatostatin analog monotherapy alone. ALXN2420 aims to address this need by providing a dual mechanism approach combining growth hormone receptor antagonism with somatostatin analog therapy.
Approved therapies include octreotide, lanreotide (somatostatin analogs), and pegvisomant (GHR antagonist). In Phase 3 development are Paltusotine (Crinetics), CAM2029 (Camurus), and Debio 4126 (Debiopharm). GHR-LRx (Ionis) is also in Phase 2.
Pegvisomant is an approved GHR antagonist used as monotherapy. ALXN2420 is being developed as a combination therapy with somatostatin analogs, offering a dual mechanism approach potentially providing superior efficacy for patients inadequately controlled on somatostatin analogs alone.
The Phase 2 trial is enrolling adult participants with acromegaly. The target population likely includes patients with inadequate response to somatostatin analog monotherapy, though specific inclusion/exclusion criteria have not been disclosed.
No approval timeline has been disclosed. ALXN2420 is in Phase 2; typical development timelines would suggest Phase 3 initiation in the coming years, with approval (if successful) several years beyond that.
No partnership or licensing agreements have been disclosed. ALXN2420 is being developed by Alexion Europe SAS.
Acromegaly is a rare chronic disease with significant unmet medical need. Improved therapeutic options that enhance efficacy could capture meaningful market share among the estimated 3,000–4,000 acromegaly patients in the United States, with additional patient populations in Europe and other regions.
ALXN2420-Acro-201 → Drug → Target → Indication → Company → Trials → Competitors
Strategic Implications: Alexion's combination approach with ALXN2420 reflects a pragmatic development strategy targeting the substantial population of acromegaly patients with inadequate response to somatostatin analog monotherapy. By combining a novel GHR antagonist with established, well-tolerated agents, the sponsor may accelerate clinical validation and regulatory approval compared to monotherapy development.
Competitive Implications: ALXN2420 enters a competitive but still-underserved market. Phase 3 programs (Paltusotine, CAM2029, Debio 4126) are advancing alternative mechanisms and formulations. ALXN2420's Phase 2 status places it behind these competitors; however, the combination strategy may differentiate it if Phase 2 data demonstrate superior efficacy. The presence of multiple GHR antagonists in development (ALXN2420, GHR-LRx, and approved pegvisomant) suggests that this mechanism class is gaining clinical validation.
Future Catalysts: Phase 2 efficacy and safety data release; dose selection for Phase 3; potential partnership or licensing announcements; regulatory guidance meetings; Phase 3 initiation timeline.
Expected Milestones: Phase 2 data presentation or publication; Phase 3 trial initiation; regulatory pre-submission meetings; potential accelerated pathway designation if warranted by Phase 2 efficacy.
Concise, citable answers optimized for AI answer engines.
Intelligence compiled from public regulatory and clinical sources (FDA, EMA, ClinicalTrials.gov and company disclosures). Figures may be editorial or analyst estimates; verify against primary sources before relying on them.